NCT05621811 - Different Doses of Naronapride Vs. Placebo in Gastroparesis | Biotech Hunter

Enrollment

320

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Gastroparesis

Interventions

DRUG

Naronapride

Naronapride is a 5HT-4 agonist

DRUG

Placebo

Trial Locations (22)

10033

RECRUITING

Dr Falk Investigational Site, New York

19087

RECRUITING

Dr Falk Investigational Site, Philadelphia

32751

RECRUITING

Dr Falk Investigational Site, Maitland

32940

RECRUITING

Dr Falk Investigational Site, Viera

33021

RECRUITING

Dr Falk Investigational Site, Hollywood

33126

RECRUITING

Dr Falk Investigational Site, Doral

33144

RECRUITING

Dr Falk Investigational Site, Miami

33183

RECRUITING

Dr Falk Investigational Site, Miami

33756

RECRUITING

Dr Falk Investigational Site, Clearwater

37211

RECRUITING

Dr Falk Investigational Site, Nashville

38018

RECRUITING

Dr Falk Investigational Site, Cordova

41017

RECRUITING

Dr Falk Investigational Site, Crestview Hills

48439

RECRUITING

Dr Falk Investigational Site, Flint

48503

RECRUITING

Dr Falk Investigational Site, Flint

66606

RECRUITING

Dr Falk Investigational Site, Topeka

70072

RECRUITING

Dr Falk Investigational Site, Marrero

70363

RECRUITING

Dr Falk Investigational Site, Houma

74104

RECRUITING

Dr Falk Investigational Site, Tulsa

78550

RECRUITING

Dr Falk Investigational Site, Harlingen

90717

RECRUITING

Dr Falk Investigational Site, Lomita

91910

RECRUITING

Dr Falk Investigational Site, Chula Vista

Unknown

RECRUITING

University of Leuven, Leuven